UnknownNot Applicable

A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

United States700 participantsStarted 2013-01

Plain-language summary

This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this naturalistic grouping of patients with various stages of cognitive loss and diagnosed with various types of dementia.

Who can participate

Age range55 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals between the ages of 55 and 89 years old * Meeting criteria for Mild Cognitive Impairment or dementia with a minimum MOST score of 5 but not over 23 * Has a minimum of 3 months evaluation * Able to undergo testing for cognition and complete the GDS Exclusion Criteria: * Known allergy/intolerance to any ingredient in Cerefolin NAC® * Substantial impediments to adherence, such as severe dementia without caregiver to administer medication * Inability to swallow pill-form medication * Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease * Hcy score lower than 11

What they're measuring

Change from Baseline in Levels of Homocysteine Over Time

Timeframe: Week 6, Week 12, and Quaterly Thereafter @ 6 Month Intervals

Trial details

NCT IDNCT01594541

SponsorPamlab, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-08

View on ClinicalTrials.gov More Mild Cognitive Impairment trials